The global leukemia cancer market is anticipated to grow at a considerable CAGR of 5.1% during the forecast period. Increasing investments in the healthcare sector and the rising development of new drugs and therapeutics will drive the market in the forecast period. According to WHO, globally leukemia cancer is considered to be the most common blood cancer. Thus, to treat and cure rising incidences of cancer across the globe, drug manufacturers and market players are conducting several R&D activities. For instance, in March 2022, Sumitomo Dainippon Pharma Oncology, Inc., a clinical-stage pharmaceutical company focused on R&D for novel cancer therapeutics, today announced that the first patient has been dosed in the Phase 1/2 study of DSP-5336, an inhibitor of melanin binding to mixed-lineage leukemia (MLL) protein, in patients with relapsed or refractory acute myeloid leukemia (AML) or acute lymphocytic leukemia (ALL).
A full report of Leukemia Cancer Market is available at: https://www.omrglobal.com/industry-reports/leukemia-cancer-market
In September 2021, Intas Pharmaceuticals Ltd announced the launch of Azadine-O, an oral Azacitidine therapy for Acute Myeloid Leukemia (a type of blood cancer), a first for the Indian market. Oral Azacitidine is approved for use in maintenance therapy for adult patients with Acute Myeloid Leukaemia. It can improve survival by almost 10 months and bridge a long-pending unmet need in cancer therapy.
Further, in December 2020, Jazz Pharmaceuticals plc announced that the company has initiated the submission of a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) seeking marketing approval for JZP-458 for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) in adult and pediatric patients who have developed hypersensitivity or silent inactivation to E. coli-derived asparaginase.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/leukemia-cancer-market
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
o By Type
o By Diagnose & Monitor
o By Treatment
- Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
- Competitive Landscape- including Bristol-Myers Squibb, Celgene Corp., Daiichi Sankyo Co., Ltd., F. Hoffmann-La Roche Ltd., and others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Leukemia Cancer Market Report Segment
By Type
- Acute Myeloid Leukemia (AML)
- Chronic Myeloid Leukemia (CML)
- Acute Lymphoblastic Leukemia (ALL)
- Chronic Lymphocytic Leukemia (CLL)
By Diagnose & Monitor
- Blood Test
- Bone Marrow Test
- Imaging Test
- Lymph Node Biopsy
- Lumbar Puncture
- Urine Test
By Treatment
- Chemotherapy
- Radiation Therapy
- Targeted Therapy
- Biological Therapy
- Stem Cell Therapy
